pyrimidine has been researched along with Multiple Myeloma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berghuis, AM; Gómez Palou, M; Huang, XF; Lacbay, CM; Park, J; Sebag, M; Ta, V; Tsantrizos, YS; Vincent, F; Waller, DD | 1 |
| Akutsu, M; Furukawa, Y; Hiraoka, N; Kano, Y; Kikuchi, J; Koyama, D; Mori, S; Nakamura, Y; Ueda, T; Uesawa, M; Wada, T; Yamauchi, T | 1 |
| Bai, X; Berenson, J; Geng, C; Hu, C; Leung, C; Li, Z; Liu, L; Xiang, J; Yi, L; Zhang, Z | 1 |
3 other study(ies) available for pyrimidine and Multiple Myeloma
| Article | Year |
|---|---|
Unraveling the Prenylation-Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors.
Topics: Apoptosis; Catalytic Domain; Cell Proliferation; Enzyme Inhibitors; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Multiple Myeloma; Protein Prenylation; Pyrimidines; rap1 GTP-Binding Proteins | 2018 |
Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Cytarabine; DNA Damage; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Inhibitory Concentration 50; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Multiple Myeloma; Pyrimidines; Rituximab | 2014 |
Synthesis and Evaluation of 2-Alkylthio-4-(N-substituted sulfonamide)pyrimidine Hydroxamic Acids as Anti-myeloma Agents.
Topics: Antineoplastic Agents; Humans; Hydroxamic Acids; Multiple Myeloma; Pyrimidines | 2016 |